 This is an open-label, non-randomized, multi-center, phase II trial of brentuximab vedotin to evaluate ORR primarily in patients with EBV- and CD30-positive lymphomas. The ORR will be evaluated based on the revised Chesons criteria or modified SWAT criteria in case of cutaneous EBV- and CD30-positive lymphomas. 